Home
Search
Study Topics
Glossary
|
Study 6 of 2400 for search of: | United States, Kentucky |
Previous Study | Return to Search Results | Next Study |
|
|
|
|
|
Sponsors and Collaborators: |
Southwest Oncology Group National Cancer Institute (NCI) Eastern Cooperative Oncology Group North Central Cancer Treatment Group Radiation Therapy Oncology Group |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00004011 |
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if surgery plus combination chemotherapy is more effective than surgery alone for non-small cell lung cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of surgery with or without combination chemotherapy in treating patients who have non-small cell lung cancer.
Condition | Intervention | Phase |
---|---|---|
Lung Cancer |
Drug: carboplatin Drug: paclitaxel Procedure: conventional surgery |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Active Control |
Official Title: | A Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Paclitaxel/Carboplatin in Clinical Stage IB (T2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer (NSCLC) |
Study Start Date: | October 1999 |
OBJECTIVES:
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to clinical stage (IB or IIA vs IIB or IIIA).
Patients are randomized to one of two treatment arms:
Patients are followed every 3 months for 1 year, every 6 months for 5 years, and then annually until year 10.
PROJECTED ACCRUAL: A total of 600 patients (300 per treatment arm) will be accrued for this study within 4 years.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically or cytologically proven non-small cell lung cancer (NSCLC), meeting 1 of the following staging criteria:
Stage II
Selected stage IIIA with negative mediastinoscopies
No symptomatic tumors (T3, N0 or T3, N1) involving the superior sulcus
Bidimensionally measurable or evaluable disease by chest x-ray or contrast-enhanced CT scan
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Pulmonary:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
Study Chair: | Paul A. Bunn, MD | University of Colorado at Denver and Health Sciences Center |
Study Chair: | Joseph A. Treat, MD | Fox Chase Cancer Center CCOP Research Base |
Study Chair: | Randolph S. Marks, MD | Mayo Clinic |
Study Chair: | Corey J. Langer, MD | Fox Chase Cancer Center |
Study ID Numbers: | CDR0000067223, SWOG-S9900, ECOG-S9900, NCCTG-S9900, RTOG-L0015 |
Study First Received: | November 1, 1999 |
Last Updated: | October 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00004011 |
Health Authority: | United States: Federal Government |
stage I non-small cell lung cancer stage II non-small cell lung cancer stage IIIA non-small cell lung cancer |
Thoracic Neoplasms Non-small cell lung cancer Respiratory Tract Diseases Paclitaxel Lung Neoplasms |
Lung Diseases Carboplatin Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Therapeutic Uses Mitosis Modulators Tubulin Modulators Antimitotic Agents Antineoplastic Agents, Phytogenic Pharmacologic Actions |